# ERCC1

Source: https://onco.cc/targets/ercc1/  
OnCo record `ercc1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ERCC1 (DNA excision repair protein ERCC-1) is a gene. The public catalogues list it as a drug target, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Bladder & urothelial cancer, Mesothelioma, Ovarian cancer and 1 more.

## Summary

Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). Participates in the processing of anaphase bridge-generating DNA structures, which consist in incompletely processed DNA lesions arising during S or G2 phase, and can result in cytokinesis failure.

CIViC holds 11 clinical evidence items and 0 assertions across 3 variants, naming Gemcitabine, Cisplatin, Platinum Compound and Paclitaxel and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: ERCC excision repair 1, endonuclease non-catalytic subunit; DNA excision repair protein ERCC-1; RAD10
- Tags: cancer-genes-wave
- Symbol: ERCC1
- Class: other
- Biology: Non-catalytic component of a structure-specific DNA repair endonuclease responsible for the 5'-incision during DNA repair. Responsible, in conjunction with SLX4, for the first step in the repair of interstrand cross-links (ICL). Participates in the processing of anaphase bridge-generating DNA structures, which consist in incompletely processed DNA lesions arising during S or G2 phase, and can result in cytokinesis failure. Also required for homology-directed repair (HDR) of DNA double-strand breaks, in conjunction with SLX4. Not functional in the nucleotide excision repair pathway. Not functional in the nucleotide excision repair pathway. Location: Nucleus; Cytoplasm (UniProt). Locus 19q13.32 (HGNC).
- Where found: Bladder & urothelial cancer: CIViC evidence names this disease; Mesothelioma: CIViC evidence names this disease; Ovarian cancer: CIViC evidence names this disease; Non-small-cell lung cancer: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 6 therapies; CIViC holds 11 clinical evidence items on its variants; UniProt keyword "DNA repair". Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:3433: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3433
- UniProt P07992: https://www.uniprot.org/uniprotkb/P07992/entry
- NCBI Gene 2067: https://www.ncbi.nlm.nih.gov/gene/2067
- Ensembl ENSG00000012061: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000012061

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)

---
JSON: https://onco.cc/api/v1/entities/ercc1.json